A Comprehensive Quality Meta-Review of Genetic and Pharmacogenomic Aspects of Medication-Related Osteonecrosis of The Jaw (MRONJ)
Source abstract
Abstract
Background: Antiresorptive and antiangiogenic medications can cause a serious adverse effect known as medication-related osteonecrosis of the jaw (MRONJ). In recent years, a new trend of research has emerged emphasizing the potential relation of MRONJ and genetic predisposition. Current evidence-based science of this adverse reaction is associated with poorly performed studies. Additionally, MRONJ research has recently observed a new trend of studies orientated towards the misuse of reviews. This quality meta-review intends to summarize the results of all systematic reviews and meta-analyses that have been published on MRONJ in relation to genetic and pharmacogenomics risk factors. Methods: The research study protocol was registered into the database of the International Network for the Registration of Systematic Reviews and Meta-Analyses (INPLASY) INPLASY202230002. A comprehensive search across several databases (PubMed, EMBASE, MEDLINE, and CINAHL) was conducted to locate multi-language papers published between January 2003 and November 2022. Data were collected from relevant research studies and appraised in accordance with the precise outcomes described in this evaluation. Results: Only five systematic reviews and meta-analyses were analysed in this meta-review. All the reviews included in this research presented qualities mistakes and shortcomings. Two quality assessment tools (Confidence in Evidence from Reviews of Qualitative research (CERQual) and Assessment of Multiple Systematic Reviews 2 (AMSTAR-2)) were used to evaluate each study included in this research. Conclusions: The data evaluated by this meta-review confirmed the poor-quality secondary research underpinning the genetic/pharmacogenomics aspect of MRONJ. Moreover, this study highlighted the many flaws of the current published systematic and meta-analysis studies published so far.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bone health and treatments · Bone and Joint Diseases · Cancer Diagnosis and Treatment
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Division of Dentistry, Oral Surgery Department, School of Medical Sciences, The University of Manchester, Manchester M13 9PL, UK
Oral Surgery Department, King’s College Hospital NHS Trust, London SE5 9RS, UK
Division of Oral and Maxillofacial Surgery, Universidad de La Frontera, Temuco 1145, Chile
Oral Surgery Department, Dental School, Fluminense Federal University, Niteroi 24210-201, RJ, Brazil
Anaesthetic & Critical Care, University of Campania Luigi Vanvitelli, 81100 Caserta, Italy
Private Practice, 50122 Florence, Italy
Dental Research Administration, Department of Periodontology, Tufts University School of Dental Medicine, Boston, MA 02111, USA
Oral and Maxillofacial Surgery Department, Hospital Leforte/DASA and Instituto de Ensino e Pesquisa Hospital Sirio-Libanes, Morumbi 05615-190, SP, Brazil
References (61)
Show source-provided references
1. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ10.1016/j.jocd.2016.09.005 ↗
2. Review and update on drugs related to the development of osteonecrosis of the jaw10.4317/medoral.23191 ↗
3. ESMO Guidelines Working Group. Bone health in cancer patients: ESMO Clinical Practice Guidelines10.1093/annonc/mdu103 ↗
4. Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies10.1016/j.amjmed.2017.03.002 ↗
5. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic10.1016/S0278-2391(03)00720-1 ↗
6. Osteonecrosis and osteomyelitis of the jaw associated with tumour necrosis factor-alpha (TNF-α) inhibitors: A systematic review10.1016/j.bjoms.2019.09.023 ↗
7. The role of illicit drugs in developing medication-related osteonecrosis (MRONJ): A systematic review10.1016/j.bjoms.2020.08.079 ↗
8. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update10.1016/j.joms.2014.04.031 ↗
9. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update10.1016/j.joms.2022.02.008 ↗
10. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: A cohort study10.1016/j.ijom.2012.06.020 ↗
11. RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): Non bis in idem?10.1007/s00520-010-1061-0 ↗
12. Antiangiogenic therapy for cancer: An update10.1002/phar.1147 ↗
13. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone10.1159/000201931 ↗
14. Prevention of medication-related osteonecrosis of the jaws secondary to tooth extractions. A systematic review
15. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: A systematic review10.1016/j.ijom.2015.01.026 ↗
16. Bisphosphonate—Related osteonecrosis of the jaws: The point of view of the oral pathologist
17. Bisphosphonate-related osteonecrosis of the jaws—Characteristics, risk factors, clinical features, localization and impact on oncological treatment10.1016/j.jcms.2011.05.003 ↗
18. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: Sunitinib10.1097/01.cad.0000361534.44052.c5 ↗
19. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases10.1016/j.ctrv.2018.06.007 ↗
20. Pathophysiology of Osteonecrosis of the Jaws10.1016/j.coms.2015.06.001 ↗
21. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases10.1093/annonc/mdr435 ↗
22. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: A genome-wide single nucleotide polymorphism analysis10.1182/blood-2008-04-147884 ↗
23. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update10.1002/cpt.597 ↗
24. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy10.1002/cpt.1409 ↗
25. A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer
26. CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma10.3324/haematol.2011.042572 ↗
27. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw
28. Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: An overview with recommendations for prevention and treatment10.1111/j.1445-5994.2008.01824.x ↗
29. The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network10.1093/annonc/mdn796 ↗
30. Management of patients at risk of bisphosphonate osteonecrosis in maxillofacial surgery units in the UK10.1016/S1479-666X(09)80062-0 ↗
31. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: Executive summary of recommendations from the American Dental Association Council on Scientific Affairs10.14219/jada.archive.2011.0108 ↗
32. Guidelines for supportive care in multiple myeloma 201110.1111/j.1365-2141.2011.08574.x ↗
33. Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus10.1002/jbmr.2405 ↗
34. Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons10.11005/jbm.2015.22.4.151 ↗
35. Position paper on medication-related osteonecrosis of the jaw (MRONJ)10.1007/s10354-016-0437-2 ↗
36. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw10.1007/s00774-016-0810-7 ↗
37. Scottish Dental Clinical Effectiveness Programme (SDCEP) (2022, September 22). Oral Health Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw. Available online: https://www.sdcep.org.uk/media/m0ko0gng/sdcep-oral-health-management-of-patients-at-risk-of-mronj-guidance-full.pdf_.
38. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
39. Schardt, C., Adams, M.B., Owens, T., Keitz, S., and Fontelo, P. (2007). Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med. Inform. Decis. Mak., 15.10.1186/1472-6947-7-16 ↗
40. Association between CYP2C8 (rs1934951) polymorphism and bisphosphonate-related osteonecrosis of the jaws in patients on bisphosphonate therapy: A meta-analysis10.1159/000342120 ↗
41. Pharmacogenomics in medication-related osteonecrosis of the jaw: A systematic literature review
42. Pharmacogenetics of medication-related osteonecrosis of the jaw: A systematic review and meta-analysis10.1016/j.ijom.2019.07.016 ↗
43. Genetic predisposition for medication-related osteonecrosis of the jaws: A systematic review10.1016/j.ijom.2019.04.014 ↗
44. Pharmacogenomics of osteonecrosis of the jaw10.1016/j.bone.2019.04.010 ↗
45. AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both10.1136/bmj.j4008 ↗
46. Lewin, S., Glenton, C., Munthe-Kaas, H., Carlsen, B., Colvin, C.J., Gülmezoglu, M., Noyes, J., Booth, A., Garside, R., and Rashidian, A. (2015). Using qualitative evidence in decision making for health and social interventions: An approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual). PLoS Med., 12.10.1371/journal.pmed.1001895 ↗
47. Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: The role of RBMS310.1634/theoncologist.2011-0202 ↗
48. Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw10.1016/j.ijom.2011.02.002 ↗
49. Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws10.1111/j.1600-0714.2010.01004.x ↗
50. A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: Analysis by DMET microarray profiling10.1111/j.1365-2141.2011.08622.x ↗
51. Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw
52. New approach to analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw10.1111/j.1601-0825.2012.01912.x ↗
53. An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jaw10.2217/bmm.12.14 ↗
54. Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw10.1016/j.jcms.2012.10.018 ↗
55. Genetic association between VEGF polymorphisms and BRONJ in the Korean population10.1111/odi.12355 ↗
56. Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy10.1080/10428194.2017.1300889 ↗
57. Kim, J.H., Ko, Y.J., Kim, J.Y., Oh, Y., Hwang, J., Han, S., Kim, S., Lee, J.H., and Han, D.H. (2015). Genetic investigation of bisphosphonate-related osteonecrosis of jaw (BRONJ) via whole exome sequencing and bioinformatics. PLoS ONE, 10.10.1371/journal.pone.0118084 ↗
58. Bioinformatics analyses of differentially expressed genes associated with bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma10.2147/OTT.S88463 ↗
59. SIRT1/HERC4 locus associated with bisphosphonate-Induced osteonecrosis of the jaw: An exome-wide association analysis10.1002/jbmr.3285 ↗
60. Tyagi, A.M., Srivastava, K., Mansoori, M.N., Trivedi, R., Chattopadhyay, N., and Singh, D. (2012). Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: A new candidate in the pathogenesis of osteoporosis. PLoS ONE, 7.10.1371/journal.pone.0044552 ↗
61. OCEBM levels of evidence system